In the years following the COVID-19 pandemic, the firms working closest to biotech investment were calling it a “nuclear winter.” Deal-making had stalled, investment committees had gone qui
The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.
Behaviour is the layer that lifestyle, physical performance, and nutrition – together – occupy.
2026 marks a significant evolution for BIO-Europe.
AI has kickstarted a new wave of innovation in biopharma R&D.
Editor's Picks
